NLRP3 Inflammasome in Aging and Neurodegeneration
Current understanding
The NLRP3 inflammasome is a cytosolic multiprotein sensor that converts upstream signals (mtDNA leak, oxidized lipids, protein aggregates, lysosomal damage) into IL-1β/IL-18 release and pyroptosis, and is repeatedly implicated across aging-tissue contexts (T2DM–AD balance circuits, Gaucher microglia, AT2R-deficient hearts, LMNA progeria) as a convergent inflammatory effector [expert-opinion]. A 2026 review proposes it as one leg of a self-sustaining Autophagy–Senescence–Inflammasome (ASI) triad in brain aging and neurodegeneration [expert-opinion]. Human translation remains inferential — most direct evidence is preclinical or mechanistic, and inflammasome-targeted drugs have not demonstrated healthspan effects.
Evidence log
- 2026-11-09 — TMAO regulates renal tubular epithelial cell senescence through circVmn2r1.: cross-connection with gut-microbiota-healthspan: [animal-model] Mouse and renal tubular epithelial cell evidence links the gut-associated metabolite TMAO to NLRP3 inflammasome activation through circVmn2r1, connecting microbial metabolite signaling with renal senescence; conservation of this pathway and intervention benefit in humans remain unestablished. (novelty: 3)
- 2026-10-05 — Electroacupuncture Targeting the NLRP3 Inflammasome in Senescence‑associated Cognitive Impairment: Mechanistic Synthesis and Meta‑analysis of Clinical Randomized Controlled Trials.: 2026 meta-analysis of 9 electroacupuncture RCTs in MCI/early AD (n≈599) reports lower IL-6 and short-term MoCA/MMSE improvement, with a mechanistic synthesis positioning NLRP3 inflammasome dampening as the proposed upstream axis — human cytokine signal is downstream and consistent with NLRP3 attenuation but does not directly measure inflammasome activity in patients. [human-rct] (novelty: 3)
- 2026-10-06 — Multimodal Technology-Driven aging Research: Decoding the Mitochondria‒Pyroptosis axis in muscle atrophy and cognitive decline.: cross-connection with mitochondrial-dysfunction: The proposed mitochondria–pyroptosis axis explicitly chains oxidative mtDNA release to NLRP3 inflammasome activation as the shared mechanistic bridge from bioenergetic failure to tissue pyroptotic hotspots in aging muscle and brain. (novelty: 3)
- 2026-09-28 — Functional Shift of NLRP3 Inflammasome Activity in Aged Macrophages.: 2026 preclinical macrophage study reframes aged-macrophage NLRP3 activity as a regulator of the apoptosis–senescence balance rather than primarily a proinflammatory cytokine driver, with MCC950 inhibition paradoxically increasing senescent cell burden — complicates the inflammasome-inhibitor-as-anti-aging pitch. [mechanism-plausible] (novelty: 3)
- 2026-07-08 — The autophagy-senescence-inflammasome axis: A novel triad in neurodegenerative diseases?: cross-connection with cellular-senescence: ASI-axis review ties glial senescence (SASP, DAMPs) to inflammasome activation as reciprocal amplifiers — SASP primes NLRP3; inflammasome-derived IL-1β reinforces senescence entry in bystander glia. (novelty: 3)